AcelRx is currently seeking commercial and development partners on a global basis for our pipeline of product candidates. Our ideal partners have both broad geographic coverage and a demonstrated track record of success in our target markets.
Our lead asset, Zalviso™, currently under NDA and MAA regulatory review by US FDA and EMA, respectively, is focused on the treatment of moderate to severe acute pain in the hospital setting. Zalviso™ is partnered with Grünenthal for Europe and Australia and has been granted a CE mark by BSI for the device. We are currently seeking additional commercialization partners for Zalviso™ in Asia, Latin America and ROW.
ARX-04 is a non-invasive, healthcare provider administered, fast-onset single dose sublingual sufentanil tablet for treatment of patients with moderate-to-severe acute pain in a number of medically supervised settings such as emergency room, ambulatory surgery, short term in-patient analgesia, paramedics bag, disaster relief / military applications. ARX-04 is currently in Phase 3 development and we plan to actively seek ex-US commercialization partners upon the completion of our Phase 3 program later this year.
Our pipeline products in cancer breakthrough pain (ARX-02) and procedural sedation (ARX-03) have all successfully completed Phase 2 studies. We are interested in discussing collaborations to complete development and registration of these product candidates on a regional or worldwide basis to maximize the therapeutic and commercial potential of our pipeline.
We welcome the opportunity to talk with potential commercialization partners worldwide about licensing relationships, development collaborations, and strategic alliances that complement and extend our own development and commercial capabilities. To discuss potential partnering opportunities, please contact:
Meera Desai, Ph.D.
Director, Alliance Management and Corporate Development